Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin to prevent chronic lung disease of prematurity in preterm infants
2018-001109-99Phase 3Unknown
- Sponsor
- Cardiff University
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bronchopulmonary dysplasia (BPD) and hyaline membrane disease (RDS) comparing Azithromycin with Placebo (2 arms). Primary endpoints: Survival without moderate or severe chronic lung disease of prematurity and Death by 36 weeks postmenstrual age. Status: unknown.
02
Drugs
azithromycin
03
Conditions
bronchopulmonary dysplasia (BPD)hyaline membrane disease (RDS)
Beyond the preview
Go deeper on 2018-001109-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001109-99.